Tofacitinib Reduces KL-6 Levels in Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease. Results Of A Phase II Investigator-Initiated Study.

Study limitation reported by the research below: “Nine patients received concomitant nintedanib, which may confound both safety and biomarker outcomes despite subgroup analysis.”